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SUMMARY
Members of sirtuin family regulate multiple critical biological processes, yet their role in carcinogenesis
remains controversial. To investigate the physiological functions of SIRT2 in development and tumorigenesis,
we disrupted Sirt2 in mice. We demonstrated that SIRT2 regulates the anaphase-promoting complex/cyclo-
some activity through deacetylation of its coactivators, APCCDH1 and CDC20. SIRT2 deficiency caused
increased levels of mitotic regulators, including Aurora-A and -B that direct centrosome amplification, aneu-
ploidy, and mitotic cell death. Sirt2-deficient mice develop gender-specific tumorigenesis, with females
primarily developingmammary tumors, andmales developing more hepatocellular carcinoma (HCC). Human
breast cancers and HCC samples exhibited reduced SIRT2 levels compared with normal tissues. These data
demonstrate that SIRT2 is a tumor suppressor through its role in regulating mitosis and genome integrity.
INTRODUCTION
In yeast, silence information regulator 2 (Sir2), a histone deace-
tylase, acts as a chromatin silencer to regulate gene expression,
DNA recombination, genomic stability, and aging (Guarente and
Kenyon, 2000). Inmammals, sirtuins constitute a gene family of 7
(SIRT1-7) NAD+-dependent type III histone and protein deacety-
lases that share homology with Sir2 (Finkel et al., 2009; Li and
Kazgan, 2011; Saunders and Verdin, 2007). It has been shown
that SIRT1, 6, and 7 primarily localize to the nucleus, whereas
SIRT3, 4, and 5 are present in mitochondria (Haigis and Sinclair,
2010; Li and Kazgan, 2011; Saunders and Verdin, 2007). SIRT2 is
predominantly localized in the cytoplasm where it colocalizes
with and deacetylates microtubules (North et al., 2003). During
mitosis, SIRT2 is localized to the chromosome and serves as
a histone deacetylase with a preference for histone H4 lysine
16 (H4K16Ac), and may regulate chromosomal condensation
during mitosis (Inoue et al., 2007; Vaquero et al., 2006). SIRT2
is also associated with mitotic structures, including the centro-
some, mitotic spindle, and midbody during mitosis, presumably
to ensure normal cell division (North and Verdin, 2007).
Progression of mitosis is also regulated by the anaphase-
promoting complex/cyclosome (APC/C), a multisubunit member
of the RING finger family of ubiquitin ligases. APC/C is com-
posed of many different subunits, including APC1-8, APC9-11,
and CDC26 (Peters, 2006; Pines, 2009). APC/C recognizes its
Significance
Although the connection between chromatin maintenance, carcinogenesis, and aging is well established, the underlying
mechanism remains elusive. During mitosis, SIRT2 is relocalized from the cytoplasm to the nucleus and associates with
chromosome and mitotic structures. Nonetheless, the function of SIRT2 in the nucleus and its deacetylation targets are
unclear. We hypothesized that SIRT2 is a fidelity protein that ensures normal mitotic progression and genetic stability.
This work shows that SIRT2 plays a critical role in maintaining the mitosis through modulating the activity of APC/C via de-
acetylation of the coactivator proteins CDH1 and CDC20 and regulating their interaction with CDC27. This finding identifies
SIRT2 as a positive regulator of APC/C activity ensuring normal mitotic progression that is critical for maintaining genome
integrity and suppressing tumorigenesis.
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substrates through two adaptor proteins, CDH1 and CDC20,
which serve as coactivators for APC/C through binding to sub-
strates at different phases of mitosis (Peters, 2006; Pines,
2009). In mammalian cells, CDC20 activates APC/C in early
mitosis until anaphase, whereas CDH1 acts in late mitosis and
during G1 phase (Pines, 2006). APC/C mediates ubiquitination
of many protein substrates that have distinct functions during
mitosis, including Aurora-A and -B, cyclins-A and -B, survivin,
Plk1, Nek2A, and securin (Li and Zhang, 2009). Although both
SIRT2 and APC/C play important functions during mitosis, the
relationship between these proteins is unknown.
Currently, all sirtuins, except for SIRT2, have been knocked
out in mice by gene targeting (Ahn et al., 2008; Cheng et al.,
2003; Haigis et al., 2006; Jacobs et al., 2008; Lombard et al.,
2007; McBurney et al., 2003; Mostoslavsky et al., 2006; Naka-
gawa et al., 2009; Vakhrusheva et al., 2008; Wang et al.,
2008a). Studies of these mutant mice have provided useful infor-
mation regarding sirtuin function in many important processes,
including cell fate determination, DNA damage repair, neuronal
protection, adaptation to calorie restriction, organ metabolism
and function, age-related diseases, and tumorigenesis, although
Figure 1. SIRT2 Deficiency Reduces Proliferation
of MEFs but Does Not Affect Animal Survival
(A) Western blot analysis of proteins extracted from adult
Sirt2+/+ (+/+) and Sirt2/ (/) mice. WT mice have two
forms of SIRT2, 43 KD and 37KD, and both are absent in
mutant mice.
(B) Number of predicted and actual offspring from inter-
breeding of heterozygous mice.
(C and D) Growth curve of Sirt2+/+ and Sirt2/MEFs from
passages (C) 1–7, and (D) 20–58 (MEFs cells from at least
five pairs of embryos were analyzed in this experiment).
(E) BrdU incorporation of MEFs released from serum
starvation.
(F–H) Chromosome spread (F) and summary of chromo-
some number from wild-type and SIRT2/ MEFs at (G)
P2, and at (H) P35 (three pairs at each passage). The
chromosome number of three primary tumors from (2)
mammary gland and (1) liver was also included in (H). Data
are presented as average ± SD. Scale bars represent
10 mm in (F). See also Figure S1.
much of the information has come from studies
of SIRT1 (Ahn et al., 2008; Deng, 2009; Finkel
et al., 2009; Jacobs et al., 2008; Kim et al.,
2010; Saunders and Verdin, 2007; Wang et al.,
2008a, 2008b). To study the physiological func-
tion of SIRT2, we have disrupted the Sirt2 gene
in mice and reported our findings below.
RESULTS
Impaired Mitotic Function Due to SIRT2
Deficiency
The Sirt2 gene was disrupted by deleting exons
5–8, which encodes the entire catalytic domain
(Figures S1A–S1C available online). Western
blot analysis revealed that there was no trun-
cated protein in embryos homozygous for the
mutation (Figure 1A), suggesting the creation of a candidate
null mutation of SIRT2. Despite expression of SIRT2 in multiple
tissues (Figure S1D), Sirt2/ mice presented at weaning in a
Mendelian ratio (Figure 1B) and developed normally (Figures
S1E and S1F). Histopathological analysis of multiple organs
also did not reveal obvious abnormalities (data not shown).
These data indicate that SIRT2 is not essential for embryonic
viability and postnatal development.
To provide a comprehensive analysis of potential abnormali-
ties associated with SIRT2 deficiency, we assessed the growth
properties of mouse embryonic fibroblasts (MEFs). The SIRT2
mutant MEFs proliferated significantly more slowly than did
wild-type (WT) controls, and stopped growing at passage P5,
one passage earlier than WT MEFs (Figure 1C). Our analysis of
P2 MEFs revealed that the reduced proliferation of mutant
MEFs was associated with decreased BrdU incorporation into
DNA (Figure 1E). Next, we performed chromosome spreads
from three pairs of mutant and WT MEFs. Our data showed
that 35% of mutant cells were aneuploid, with chromosome
numbers ranging from >40 to 80 per cell, whereas <5% of
wild-type cells were aneuploid (Figures 1F and 1G). These
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observations suggest that loss of SIRT2 resulted in reduced
cell proliferation that is associated with increased genetic
instability.
To study SIRT2 function further, we immortalized SIRT2
mutant and WT MEFs, using a 3T3 protocol. SIRT2 mutant cells
escaped senescence at P22 and increased their proliferation
and reached maximum growth at P38, whereas WT cells
escaped senescence and reached maximum growth approxi-
mately four passages later, although they gained faster growth
starting from P45 (Figure 1D). Meanwhile, our study revealed
that SIRT2/ MEFs exhibited loss of contact inhibition, as re-
flected by the formation of foci in cultured monolayer cells
(Figure S1H) and increased soft agar colony formation (Fig-
ure S1I), suggesting that some of the mutant cells may become
malignantly transformed. To investigate this hypothesis, the
immortalized MEFs were inoculated into nude mice. All mice
that received an allograft of SIRT2 mutant cells developed
tumors, whereas none were observed in those inoculated with
WT MEFs (Figure S1J). More profound genetic instability was
found in immortalized SIRT2/ MEFs and tumors (Figure 1H),
suggesting that tumorigenesis of SIRT2/ MEFs could result
from increased genetic instability.
Figure 2. Absence of SIRT2 Results in Tumor
Formation in Multiple Organs
(A) Kaplan-Meier survival curve showing cancer incidence
in SIRT2/ (n = 26), SIRT2+/ (n = 13), and WT (n = 22)
female mice.
(B and C) Histological sections of a mammary gland from
(B) wild-typemice and (C) an adenocarcinoma from SIRT2
mutant mice. Scale bars represent 10 mm.
(D) Immunofluorescent staining of an adenocarcinoma
using basal (CK14) and luminal (K18) markers. Scale bars
represent 10 mm.
(E) Kaplan-Meier survival curve showing cancer incidence
in SIRT2/ (n = 19), SIRT2+/ (n = 10), and WT (n = 20)
male mice.
(F and G) Whole-mount view (F) and histological section
(G) of a HCC from liver of SIRT2 mutant mice. Scale bars
represent 10 mm in (G).
(H and I) Proliferation assay using Ki67 staining; (H) 203
and (I) 633 magnifications. Scale bars represent 10 mm.
See also Table S1 and Figure S2.
SIRT2 Deficiency Causes Tumorigenesis
The association of SIRT2 losswith spontaneous
malignant transformation of mutant MEFs sug-
gests that SIRT2 might serve as a tumor sup-
pressor. To provide in vivo evidence, a cohort
of mice was monitored for possible tumor
formation, and it was observed that SIRT2
mutant mice exhibited a gender-specific spec-
trum of tumorigenesis. SIRT2 mutant females
started to develop tumors, primarily in the
mammary glands, at 10 months of age, with
cancer incidence reaching60% by 24months
(Figure 2A and Table S1). The mammary tumors
were poorly differentiated, with obvious nuclear
polymorphisms (Figure 2C). Notably, many cells
were positive for both basal and luminal
markers, suggesting they share a common origin (Figure 2D).
Hyperplasia in the mutant glands was also detected prior to
mammary tumor development (Figures S2A and S2B).
SIRT2 mutant male mice also developed cancers in multiple
organs, starting from 8months of age, with the cancer incidence
reaching60%by 20months of age (Figure 2E and Table S1). Of
19 SIRT2/ mice studied, five (26%) developed from the liver
(Figure 2F), two (11%) from the lung, and one each from
pancreas, stomach, duodenum, and prostate, respectively
(Figures S2D–S2G). Our analysis of liver cancers revealed that
they are hepatocellular carcinoma (HCC) with extensive cellular
proliferation (Figures 2G–2I).
SIRT2 Deficiency Caused Centrosome Amplification
Associated with Increased Expression of Aurora-A
The presence of a substantial percentage of aneuploid cells
suggests that the fidelity of chromosome segregation is com-
promised. It was shown that SIRT2 is localized on the centro-
some (North and Verdin, 2007), and our data confirmed this
(Figure S3A). Because aberrant replication of centrosomes
can lead to aneuploidy (Wang et al., 2006; Xu et al., 1999), we
next investigated whether loss of SIRT2 affects centrosome
Cancer Cell
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duplication. Using an antibody to g-tubulin, we compared the
centrosome number of Sirt2/ and wild-type MEFs at P2. Our
data showed that 31% (55/181) of Sirt2/ cells contained three
or more centrosomes, whereas only 7% (15/212) of control
MEFs contained greater than two centrosomes (Figure 3A and
Figure S3B). Profound centrosome amplification was also
observed in immortalized Sirt2/ MEFs (Figure 3A). Similar
data was obtained by using an antibody to pericentrin (data
not shown).
Aurora-A plays an essential role in centrosome replication
(Cowley et al., 2009). We previously found that overexpression
of Aurora-A causes centrosome amplification and mammary
tumor formation in mice (Wang et al., 2006). These data promp-
ted us to investigate the potential relationship between SIRT2
and Aurora-A. We observed that SIRT2 and Aurora-A interact
with each other by reciprocal immunoprecipitation (Figure 3B),
and they colocalize to the centrosome (Figure S3C). We had
Figure 3. Loss of SIRT2 Causes Centrosome
Amplification That Is Associated with Increased
Expression of Aurora-A
(A) SIRT2 deficiency results in centrosome amplification in
MEFs. Centrosome number of 181 and 175 SIRT2/ cells
were counted at passage (P) 2 and P36, whereas 212 and
120 wild-type cells were counted at P2 and P36, respec-
tively. Percentage of cells with normal number (1–2/cell)
and abnormal number (>2/cells) of centrosomes were
shown.
(B) Interaction between SIRT2 and Aurora-A (Aur-A). 293T
cells were transiently transfected with flag-SIRT2 (F-S2)
expression vector or mock vector (pCMV5), lysed with IP
buffer, and lysates were immunoprecipitated with either
anti-Flag conjugated beads (upper panel) or antibody to
endogenous Aurora-A (lower panel). Blots were immuno-
blotted with either anti-SIRT2, Flag, or Aurora-A anti-
bodies. Five percent of input was used in all panels.
(C–E) SIRT2 deficiency results in an increase of Aurora-A
protein in (C) MEFs, (D) mammary tissues (‘‘normal’’) and
mammary tumors, and (E) liver and liver tumors.
(F) shRNA-mediated acute knockdown of SIRT2 increases
Aurora-A in HepG2 cells. Two lentiviral-based shRNA
constructs against different region of SIRT2 (Sh1 and Sh2)
and control (pLKO.1-Luc) are used.
(G) Aurora-A protein is more stable in SIRT2/MEFs than
in SIRT2 WT MEFs at G1 phase. Cells were kept in serum
freemedium for 72 hr, replated in 15%FBSDMEM for 4 hr,
and then treated with 10 mg/ml of cycloheximide (CHX) at
the indicated time points before subjected to western blot.
The experiments were repeated three times and band
intensities were measured using Image Lab Version 3.0.
Statistic analysis was provided on the right panel.
*Represents Student’s p value < 0.005.
(H and I) Ectopic overexpression of SIRT2-WT, but not
SIRT2-HY reduces Aurora-A in SIRT2/ MEFs (Con:
pcDNA3.1 vector only) (H), but this effect is blocked in
the presence of 10 mM of MG132 for 24 hr (I). See also
Figure S3.
also detected significantly higher levels of
Aurora-A in SIRT2 mutant MEFs (Figure 3C),
mammary tissues (Figure 3D), and liver (Fig-
ure 3E), compared with controls. High levels of
Aurora-A were also detected in the mammary and liver tumors
from SIRT2 mutant mice (Figures 3D and 3E).
SIRT2 Interacts with and Degrades Aurora-A, Although
It Does Not Deacetylate Aurora-A
To assess whether increased expression of Aurora-A is a direct
consequence of SIRT2 deficiency, we performed shRNA-
mediated knockdown in HepG2 cells. We found that shRNA-
mediated acute knockdown of SIRT2 increased Aurora-A protein
(Figure 3F) but did not affect transcriptional levels of Aurora-A
(data not shown), suggesting that the absence of SIRT2 stabi-
lized Aurora-A at the posttranscriptional level. To verify this, we
treated MEFs with cycloheximide to block new protein synthesis
and then measured Aurora-A levels at either G1 phase or unsyn-
chronized cell population. The level of Aurora-A was reduced to
50% after 2 hr of treatment, and was almost completely dimin-
ished after 6 hr in wild-type cells (Figure 3G). In contrast, the level
Cancer Cell
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of Aurora-A was reduced to 50% after 4 hr and 30% protein
was maintained up to 8 hr of treatment in SIRT2/ cells (Fig-
ure 3G). Similar observation was also made in the unsynchro-
nized cell populations (Figure S3D).
Because SIRT2 is a well-known deacetylase and it interacts
with Aurora-A, it is conceivable that SIRT2 deacetylates
Aurora-A, which contributes to Aurora-A’s degradation. How-
ever, we were not able to detect acetylation of Aurora-A (data
not shown), suggesting that Aurora-A is not a direct target of
SIRT2 deacetylase activity, despite their interaction with each
other. Next, we investigated whether SIRT2 deacetylase activity
is involved in regulating Aurora-A stability. We transfected
SIRT2/ MEFs with WT SIRT2 (SIRT2-WT) or a deacetylation
mutant SIRT2 (SIRT2-HY) andmeasured Aurora-A levels in these
cells. Overexpression of SIRT2-WT, but not SIRT2-HY, signifi-
cantly reduced levels of Aurora-A (Figure 3H). This data suggests
that although SIRT2 does not deacetylate Aurora-A, its deacety-
lase activity is involved in regulating Aurora-A stability, perhaps
through deacetylating some other unidentified factors. We also
found that degradation of Aurora-A caused by SIRT2 overex-
pression can be blocked by treatment with the proteosome
inhibitor MG132 (Figure 3I), suggesting that Aurora-A may be
ubiquitinated before its degradation.
SIRT2 Forms a Protein Complex with
Anaphase-Promoting Complex/Cyclosome (APC/C)
To investigate the underlying mechanism how SIRT2 deficiency
affect Aurora-A stability, we performed a proteomic study to
identify interaction proteins and potential targets of SIRT2 de-
acetylase activity. After expressing a Flag-SIRT2 construct in
HeLa cells, followed by a pull-down using an antibody to Flag,
we identified several distinct protein bands on the SDS-PAGE
gel that were present in Flag-SIRT2 transfected, but not in the
vector transfected cells (Figure 4A). Analysis of these bands
using mass spectrometry identified many proteins, including
several components of APC/C and Aurora-A (Figure 4A). The
interaction of these proteins with Flag-SIRT2 was confirmed by
immunoblots with individual antibodies after pull-down with
Flag-SIRT2 (Figures 4A and 4B).
CDH1 and CDC20 are essential E3-ligases of the APC/C
complex, which serve as coactivators for APC/C and have
substrate specificity for different APC/C substrates, including
Aurora-A (Peters, 2006; Pines, 2009). Given our earlier observa-
tion that SIRT2 overexpression mediated Aurora-A degradation
is blocked by proteosome inhibitor MG132 (Figure 3I), we
hypothesized that SIRT1 might modulate Aurora-A stability
through interacting with CDH1 and CDC20. Therefore, we further
studied interactions between SIRT2 with CDH1 and CDC20.
Using reciprocal immunoprecipitation, we confirmed reciprocal
interactions of endogenous SIRT2 with CDH1 (Figures 4C and
4D) and CDC20 (Figures 4E and 4F) in wild-type MEFs, but not
in SIRT2/MEFs (Figures 4C–4F). Similar interactions between
endogenous or ectopically overexpressed SIRT2 with CDH1 and
CDC20 were also observed in HeLa cells (data not shown).
SIRT2 Deacetylates CDH1 and CDC20
and Enhances Their Binding with APC/C
Next, we tested whether SIRT2 could deacetylate CDH1 and
CDC20. We first obtained acetylated CDH1 and CDC20 from
293T cells (Figure S4A, lanes 1 and 4) and then performed an
in vitro deacetylation assay by adding purified SIRT2-WT (Fig-
ure S4A, lanes 2 and 5) or SIRT2-HY (Figure S4A, lanes 3 and
6) proteins, which showed that SIRT2-WT, but not SIRT2-HY
was able to deacetylate both proteins. A similar deacetylation
pattern was observed when 293T cells were transfected with a
SIRT2-WT construct, but not a SIRT2-HY construct (Figures S4B
and S4C). Furthermore, the acetylation of CDH1 (Figure S4D) or
Figure 4. SIRT2 Interacts with APC/C and Deacetylates CDH1 and
CDC20
(A) Mass spectrometry analysis of Flag-SIRT2-interactingproteins after
transfection of Flag-SIRT2 into HeLa cells. Lysates were immunoprecipitated
with anti-Flag-agarose beads and eluted using Flag peptide, resolved by SDS-
PAGE gel, and subjected to mass spectrometry analysis.
(B) Immunoblots of Flag-SIRT2 interacting proteins.
(C–F) Reciprocal coimmunoprecipitation of endogenous (C and D) SIRT2 and
CDH1 or (E and F) CDC20 from immortalized SIRT2+/+ and SIRT2/ MEF
cells. After synchronization using serum starvation for 72 hr, cells were
released into normal media for 16 hr and harvested for coimmunoprecipitation.
The lysates were immunoprecipitated with anti-SIRT2, -CDH1, or -CDC20
antibodies, respectively, and IPed samples were analyzed by immunoblotting
with anti-SIRT2, -CDH1, or -CDC20, respectively.
(G and H) In vivo deacetylation analysis of endogenous (G) CDH1 and (H)
CDC20 from liver of SIRT2 WT and KO mice 48 hr after partial hepatectomy.
See also Figure S4.
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CDC20 (Figure S4E) proteins was much higher in SIRT2/
than WT MEFs. shRNA specific for CDH1 (Figure S4D) or
CDC20 (Figure S4E) reduced their levels of acetylation. Alto-
gether, this data shows that SIRT2 is a potent deacetylase of
CDH1 and CDC20. To provide validation at the organism level,
we examined the acetylation status of endogenous CDH1 and
CDC20 from normal mouse liver or mouse liver 48 hr after partial
hepatectomy (hepatectomy is used to induce hepatocyte pro-
liferation and liver regeneration). Our data indicated that in the
absence of SIRT2, there was markedly increased acetylated
CDH1 in both the normal liver and the liver 48 hr after partial
hepatectomy (Figure 4G and data not shown). Our data indicated
that CDC20 was not detected in the normal liver but strongly
induced 48 hr after partial hepatectomy (data not shown), which
is consistent to an observation that CDC20 is only present in
the mitotic cells (Gieffers et al., 1999). Absence of SIRT2 sig-
nificantly increased acetylated CDC20 in the hepatectomized
lever compared with hepatectomized liver of wild-type mice
(Figure 4H).
Figure 5. SIRT2 Regulates the Function of CDH1
and CDC20 through Deacetylation
(A) Overexpression of WT but not deacetylase mutant (HY)
SIRT2 decreases CDH1 acetylation and increases its
interaction with CDC27 in HeLa cells. Ac-K: pan-acetyl
lysine antibody.
(B) Overexpression of WT but not deacetylase mutant (HY)
SIRT2 decreases CDC20 acetylation and increases its
interaction with phospho-CDC27 in HeLa cells.
(C and D) Knockdown of SIRT2 by siRNA increases
acetylation of (C) CDH1 and (D) CDC20 and decreases
interaction with CDC27 or with phospho-CDC27,
respectively, in HeLa cells. Si-S2 (siRNA against Sirt2),
Si-Con (scramble siRNA).
(E) SIRT2 deficiency increases acetylation of CDH1 and
decreases its interaction with CDC27, which is accom-
panied by an increase in Aurora-A in immortalized Sirt2 +/+
and / MEF cells.
(F) SIRT2 deficiency increases acetylation of CDC20 and
decreases its interaction with CDC27 in immortalized
SIRT2 WT and KO MEF cells. In all above panels, 24 hr
after transfection, cells were synchronized by double
thymidine block (HeLa cells) or serum starvation for 48 hr
(MEF cells), released into regular media for 12 hr or 18 hr,
respectively, Input: lysates from nontransfected and
unsynchronized cells (5% in relation to IP samples) were
used as control to distinguish phospho-CDC27 (migration
slower) and nonphospho-CDC27. See also Figure S5.
CDH1 and CDC20 activate APC/C by binding
to CDC27 (Peters, 2006; Pines, 2009). Therefore,
we determined whether deacetylation of CDH1
and CDC20 by SIRT2 could affect their interac-
tion with CDC27. In HeLa cells, we found that
expression of SIRT2-WT, but not SIRT2-HY,
reduced the acetylated form of CDH1 (Figure 5A)
andCDC20 (Figure5B), and increased their inter-
action with CDC27 (Figures 5A and 5B). Con-
versely, siRNA-mediated knockdown of SIRT2
increased acetylation of CDH1 and CDC20 and
decreased their interaction with CDC27 (Fig-
ures 5C and 5D). Furthermore, we showed that
SIRT2/ MEFs displayed hyperacetylated CDH1 (Figure 5E)
and CDC20 (Figure 5F) that was accompanied by decreased
interaction with CDC27, and these phenotypes could be reversed
by re-expression of SIRT2-WT, but not SIRT2-HY (Figures 5E and
5F). Because the interaction of CDH1 and CDC20 with CDC27
playsan important role inactivationofAPC/C (Peters, 2006;Pines,
2009), these data suggest that SIRT2 deficiency impairs APC/C
activity through causing hyperacetylation of CDH1 and CDC20,
which fail to interact with CDC27.
Next, we used mass spectrometry to identify amino acids in
these proteins that may be deacetylated by SIRT2. We detected
two potential lysine acetylation sites in CDH1 (i.e., K69 and K159)
(Figures S5A and S5B) and one in CDC20 (K66) (Figure S5C).
A single mutation of K69 or K159 to arginine (R) in CDH1 reduced
acetylation levels, whereas the combined mutations of both
sites diminished its acetylation (Figure 5G). On the other hand,
mutation of K66 to R66 in CDC20 partially reduced its acetylation
level (Figure 6A), suggesting that other unidentified site(s) could
also be acetylated. We further demonstrated that mutations of
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the acetylation sites, K69R and K159R of CDH1 (Figure 6A), and
K66R of CDC20 (Figure 6B), reduced the acetylation of these
proteins and enhanced their interaction with CDC27, which is
consistent with our earlier finding that the deacetylated form of
these proteins interact with CDC27.
Because mutation of K69R and K159R of CDH1 nearly
completely reduces the acetylated form of CDH1 and markedly
increases its interaction with CDC27 (Figure 6A), we hypothe-
sized that the nonacetylated form of CDH1 should have much
higher ability to activate APC/C compared with the acetylated
form. To investigate this, we isolated the Flag-CDH1-WT (nona-
cetylated form), Flag-CDH1-WT (acetylated form), and Flag-
CDH1-K69/159R (that cannot be acetylated) from 293 cells,
and performed in vitro APC/C activity assay using Cyclin B1
ubiquitination as reporter. Our data indicated that the acetylated
CDH1 has significantly lower APC/C activity than nonacetylated
CDH1 and the CDH1-K69/159R, whereas no significant differ-
ence is observed between the nonacetylated CDH1 and the
CDH1-K69/159R mutated CDH1 (Figure 6C).
SIRT2 Deficiency Impairs APC/C Activity, Leading
to Increased Levels of Mitotic Regulators
In light of this finding, we believe that the increased level of
Aurora-A in SIRT2mutant cells is due to impaired APC/C activity.
Figure 6. Analysis of Acetylation Sites in CDH1 and
CDC20 and Their Effect on APC/C Activity
(A and B) Mutations of (A) Cdh1 (K69R, K159R, and K69/
159R) and (B) CDC20 (K66R), which mimic the deacety-
lation of lysine residue, reduces their interaction with
CDC27, as revealed by IP against (A) HA-Cdh1 and (B)
HA-Cdc20 followed by western blot against Cdc27.
(C and D) in vitro APC/C activity assay using Cyclin B1
ubiquitination as reporter in the presence or absence of
acetylated or nonacetylated forms of (C) CDH1 and (D)
CDC20 proteins purified from 293T cells and HeLa cells,
respectively. Lane 1: reaction mix without adding CDH1 or
CDC20 proteins. Lane 2: nonacetylated forms of Flag
tagged wild-type (WT) CDH1 or CDC20. Line 3: acetylated
forms of Flag tagged wild-type (Ac-WT) CDH1 or CDC20.
Lane 4: Flag tagged CDH1-K69/159R or CDC20-K66R
(MT). Lower panels show status of acetylation of CDH1
and CDC20.
To provide evidence for this notion, we exam-
ined whether SIRT2 could affect Aurora-A
ubiquitination, because APC/C has E3 ubiquitin
ligase activity. Our data revealed that knock-
down of SIRT2 caused upregulation of Aurora-A
that is associated with decreased ubiquitination
(Figures 7A and 7B). Conversely, overexpres-
sion of SIRT2-WT, but not SIRT2-HY, de-
creased the protein level of Aurora-A through
increased ubiquitination (Figures 7C and 7D).
We also confirmed that the effect of SIRT2 on
Aurora-A stability requires CDC27, because
SIRT2 cannot reduce the protein level of
Aurora-A in CDC27 knockdown HeLa cells (Fig-
ure 7E). These data provide strong evidence
that degradation of Aurora-A by SIRT2 is medi-
ated by APC/C. Because APC/C is responsible for degrading
multiple proteins during mitosis, we hypothesized that SIRT2
deficiency might cause a broader alteration in protein abun-
dance. Therefore, we performed further analysis and detected
increased levels of multiple mitotic regulators, including
Aurora-A, Aurora-B, Plk1, securin, and cyclin A2 in SIRT2/
cells (Figure 7F). As a validation for these changes, we detected
similar results for Aurora-B as compared with Aurora-A, i.e.,
siRNA against SIRT2 increased levels of Aurora-B (Figure 7A),
whereas overexpression of SIRT2 decreased it (Figure 7C), and
such changes were blocked when CDC27 was knocked down
(Figure 7E). Consistent with the altered expression of multiple
mitotic regulators, SIRT2/ cells displayed abnormalities in
mitosis besides the centrosome amplification, including cell
death during mitosis (Figures S6B, S6D,and S6E), failure to
complete cytokinesis (Figure S6C), and arrest atmetaphase (Fig-
ure S6D), some of which were not observed in control cells
(Figures S6A and S6F).
Expression of SIRT2 in Human Tumor Samples
Our data so far indicate that SIRT2 acts as a tumor suppressor
in mice. To investigate whether SIRT2 may have a similar
function in humans, we performed a tissue array to compare
SIRT2 protein levels between 36 pairs of breast cancers and
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cancer-adjacent normal breast tissues, as well as 18 metastatic
cancers. There were significantly higher levels of SIRT2 in all
normal breast tissues as compared with cancer tissues (Figures
8A and 8B). We also analyzed SIRT2 expression levels from
microarray data containing 264 HCC samples and found
that many HCCs showed lower levels of SIRT2 than normal liver
(Figure 8C). Expression of SIRT2 was reduced by 2- to 3-fold in
44 (16.77%) tumors and by >3-fold in eight (3.03%) tumors,
whereas only three (1.14%) exhibited increased SIRT2 levels
by 2–3-fold. Expression of SIRT2 was also reduced by 1.5–2-
fold in 77 (29.17%) tumors, and increased by 1.5–2-fold in seven
(2.65%) tumors, and had no significant changes (varying
from 1.5 to +1.5) in the remaining 125 (47.35%) tumors (Fig-
ure 8D). To provide validation of the microarray data, we picked
10 HCC samples that showed reduced levels of SIRT2 and
performed real-time RT-PCR. There was a reduction of SIRT2
in eight samples, as compared with their normal controls (Fig-
ure 7E). This observation is consistent with our view that SIRT2
may play a role in human HCC development. Oncomine analysis
also showed reduced SIRT2 mRNA expression in anaplastic
oligodendroglioma, glioblastoma, clear cell renal carcinoma,
and prostate carcinoma, as compared with normal tissue
(Figure S7).
DISCUSSION
In this study, we analyzed the physiological function of SIRT2
in mutant mice generated by gene targeting. We show that
SIRT2-deficient cells displayed centrosome amplification and
cell death duringmitosis that was accompanied by genetic insta-
bility. Initially, SIRT2-deficient MEFs exhibited reduced prolifera-
tion; however, they gradually gained a faster growth rate and
becamemalignantly transformed after immortalization, suggest-
ing that the absence of SIRT2 eventually triggers tumorigenesis.
Consistently, many aged Sirt2/ mice developed tumors in
multiple tissues. These data yield important information suggest-
ing an essential role of SIRT2 in maintaining genetic stability and
repressing tumor formation.
Figure 7. SIRT2 Regulates Aurora-A Levels Mediated by APC/C
(A) Knockdown of SIRT2 by siRNA against Sirt2 (Si-S2), but not scramble siRNA (Si-Con), in HeLa cells increases expression level of Aurora-A and Aurora-B
(Aur-B) protein.
(B) Increased level of Aurora-A is correlated with reduced Aurora-A. After cotransfection with indicated plasmids and Si-S2 into HeLa cells for 24 hr, cells were
treated with 10 mM of MG132 for 4 hr. Lysates were immunoprecipitated with Flag antibody conjugated-beads, and immunoblotted with indicated antibodies.
(C) Overexpression of HA-tagged SIRT2-WT, but not SIRT2-HY (HA-S2), reduces expression levels of Aurora-A and Aurora-B compared with GFP transfected
HeLa cells.
(D) Reduces level of Aurora-A is associated with increased ubiquitination. After transfection with indicated plasmids for 24 hr, cells were treated with 10 mM of
MG132 for 4 hr. Lysates were immunoprecipitated with Flag antibody conjugated-beads, and immunoblotted with indicated antibodies.
(E) Effect of SIRT2 on the protein level of Aurora-A and -B was blocked by CDC27 knockdown. Lysates were analyzed by western blot 48 hr after cotransfection
with indicated plasmids, siRNA against Cdc27 (Si-Cdc27) or scramble siRNA (Si-Con) into HeLa cells.
(F) Western blot analysis of protein lysates in primary SIRT2 +/+ and /MEFs (Passage 2) after mitotic release for indicated time points. Cells were synchronized
by serum starvation for 72 hr, replaced with normal media containing nocodazole for 18 hr, and then mitotic cells collected were replated and harvested at
indicated time points for western blot analysis. See also Figure S6.
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SIRT2 Functions as a Tumor Suppressor
Previous investigations indicate that two members of the sirtuin
family, SIRT1 and SIRT3, have tumor suppressor function (Bell
et al., 2011; Deng, 2009; Finley et al., 2011; Kim et al., 2010;
Tao et al., 2010; Wang et al., 2008a, 2008b). Here our data sug-
gest that another member of this gene family, SIRT2, also acts
as a tumor suppressor. Current information regarding a role of
SIRT2 in tumorigenesis is scarce and conflicting. It was sug-
gested that SIRT2 might promote tumor formation because
SIRT2 deacetylates and inhibits the activity of p53 (Jin et al.,
2008; Peck et al., 2010). Consistently, dual inhibitors of SIRT1
and SIRT2 induce apoptosis in tumor cell lines (Peck et al.,
2010; Zhang et al., 2009) and inhibit growth of Burkitt lymphoma
Figure 8. SIRT2 Gene Expression in Human
Cancers
(A) Comparison of SIRT2 protein levels revealed by tissue
array in 36 pairs of primary breast cancers and adjacent
normal breast tissues, as well as nine pairs of lymph node
metastatic infiltrating ductal carcinomas and cancer
adjacent normal lymph node tissues (adj. normal). Levels
of SIRT2 staining were classified as high (Hi), medium
(Me), low (Lo), and negative (No).
(B) Examples of immunohistochemical images of three
primary cancers (1: No; 2: Lo, 3: Me), one lymph node
metastatic infiltrating ductal carcinoma (4: No), and two
adjacent normal breast tissues (5: Lo; 6: Hi). Scale bars
represent 10 mm.
(C and D) SIRT2 expression levels frommicroarray data of
264 HCC samples (C), presented as raw log2 ratio (tumor/
normal: T/N) (D). Red represents high ratio of T/N and
green represents low ratio of T/N.
(E) Real-time RT-PCR of 10 pairs of samples was also
presented. Data shown is average ± SD.
(F) A model illustrating actions of SIRT2 in regulating APC/
C activity through deacetylation of CDH1 and CDC20,
which is critical for maintaining normal mitosis. SIRT2
deficiency impairs APC/C activity, leading to mitotic
catastrophe, genetic instability, and tumorigenesis. See
also Figure S7.
xenografts (Heltweg et al., 2006), whereas an
inhibitor for SIRT1 alone did not have such an
anti-tumor effect (Peck et al., 2010) Moreover,
a greater correlation between tumor tissue and
the expression levels of SIRT2 (6 of 11) than
SIRT1 (1 of 11) was also reported (Ouaı¨ssi
et al., 2008). On the other hand, it was shown
that SIRT2 expression is downregulated in
human gliomas, and ectopic expression of
SIRT2 in glioma cell lines led to a remarkable
reduction of colony formation ability (Hiratsuka
et al., 2003). We also detected reduced expres-
sion of SIRT2 in human breast cancer and HCC,
compared to normal tissue (Figures 8A–8E). An
analysis of Oncomine datasets also revealed
reduced SIRT2 mRNA expression in anaplastic
oligodendroglioma, glioblastoma, clear cell
renal carcinoma, and prostate carcinoma, as
compared with normal tissue (Figure S7). These
data suggest that SIRT2 inhibits tumor forma-
tion, rather than promotes it. Importantly, we show that SIRT2
mutant animals developed tumors, providing strong genetic
evidence for a tumor suppressor function.
SIRT2 Is a Positive Regulator of APC/C Activity
Cells lacking Sirt2, both in vitro and in vivo, displayed wide-
spread genetic instability and abnormal mitosis both of which
can serve as causes for tumorigenesis suggesting a possible
underlying mechanisms for tumorigenesis associated with
SIRT2 deficiency. In this regard, it has been shown that SIRT2
deacetylates a-tubulin and overexpression of SIRT2 blocks
chromosome condensation in response to mitotic stress (Inoue
et al., 2007). SIRT2 downregulation was also found to confer
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resistance to microtubule inhibitors by prolonging chronic
mitotic arrest (Inoue et al., 2009). However, our data showed
that although ectopic overexpression of SIRT2 reduces a-tubulin
acetylation in cultured cells, therewere no acetylation changes in
SIRT2mutant cells and tissues (data not shown), suggesting that
SIRT2-mediated tubulin deacetylation does not play a obvious
role in promoting genetic instability and tumorigenesis in the
SIRT2 mutant mice. Instead, our analysis indicates that hyper-
acetylation of CDH1 and CDC20 reduces their interaction
with CDC27, which decreases APC/C activity; and in contrast,
deacetylation of CDH1 and CDC20 by SIRT2 enhances the inter-
action of these coactivators with CDC27, leading to activation
of APC/C. Thus, this data indicates that SIRT2 is a positive
regulator for APC/C activity.
Several lines of evidence suggest that APC/C-CDH1 is
involved in tumorigenesis. First, several APC/C-CDH1 sub-
strates, including cyclins, Aurora-A, and Plk1, are overexpressed
in human cancers and appear to promote tumor growth (Saeki
et al., 2009; Schmit et al., 2009). Second, although it is unclear
whether CDH deficiency could cause tumor formation due to
middle gestation lethality of CDH1/ embryos (Garcı´a-Higuera
et al., 2008; Li et al., 2008), CDH1-homozyous cells displayed
profound genetic instability and the heterozygousmice exhibited
increased susceptibility to spontaneous tumors (Garcı´a-Higuera
et al., 2008). These data suggest that CDH1 contributes to the
maintenance of genomic stability and acts as a haplo-insufficient
tumor suppressor. Third, it is well established that cancer cells
preferentially use glycolysis to generate energy to continue
proliferation in the aerobic conditions that is referred to as the
‘‘Warburg effect’’ (Warburg, 1956). A recent study revealed that
the proliferative response, regardless of whether it occurs in
normal or neoplastic cells, is dependent on a decrease in the
activity of CDH1 that activates both proliferation and glycolysis.
Thus, CDH1 activity may account, at least in part, for the War-
burg effect that may link glycolysis to cell proliferation (Almeida
et al., 2010).
SIRT2 Maintains the Integrity of Mitosis through
Regulating APC/C Activity
Our results also showed that Sirt2 deficiency results in genomic
instability that is associated with centrosome amplification,
mitotic cell death in early passage MEFs, and tumorigenesis at
later stages. As such, it is proposed that these abnormalities
can be caused by a combined effect of altered expression of
mitotic regulators that are regulated by APC/C. Although it is
impossible to investigate the actual influence of SIRT2 on each
of these regulators, or the impact of them on the SIRT2-depen-
dent phenotypes observed in this study, we first chose to
present Aurora-A as a mechanistic example. In this regard,
considerable data has implicated Aurora-A in genetic instability
and cancer. First, Aurora-A is localized at the centrosome and
is required for centrosome maturation and separation (Anand
et al., 2003; Giet et al., 2005), and ectopic overexpression of
Aurora-A impairs the spindle assembly checkpoint and results
in aneuploidy (Stenoien et al., 2003; Zhou et al., 1998). Second,
the absence of Aurora-A in mice causes mitotic arrest and
monopolar spindle formation (Cowley et al., 2009) and its over-
expression in mammary epithelium results in centrosome
amplification and murine mammary tumor formation (Wang
et al., 2006). Third, in addition to its effect on spindle assembly
checkpoint and centrosome duplication, Aurora-A overexpres-
sion could also activate the Akt-mTOR pathway that is involved
in a transformed phenotype (Taga et al., 2009). Indeed, overex-
pression of Aurora-A is frequently detected in several different
types of cancers, including breast malignancy (Giet et al.,
2005; Hu et al., 2005; Saeki et al., 2009; Tanaka et al., 2005;
Zhou et al., 1998). A recent study also provided data that strongly
associate the high Aurora-A expression with decreased survival
(p = 0.0005) of breast cancer patients (Nadler et al., 2008). Our
observation that mammary cancer is the predominant form of
cancers in SIRT2/ females is consistent with the high level of
Aurora-A in these mice. In addition, Garcı´a-Higuera et al.
(2008) showed that Cdh1+/ female mice developed higher
incidence of mammary tumor than other types of tumors. The
authors believed that the accumulation of genomic instability
might specifically promote the development of epithelial tumors
that typically require a genomic instability component (Garcı´a-
Higuera et al., 2008).
On the other hand, our data reveal 26% (5/19) of SIRT2/
males developed HCC, whereas it only occurred in 4% (1/26)
SIRT2/ females. This observation is consistent with the fact
that human HCC occurs at a much higher rate in males than
females (Ruggieri et al., 2010) although it may suggest that the
Aurora-A overexpression does not have a major impact on
HCC formation, or alternatively, its effect is compromised due
to the presence of some protective factors in females. Although
the role of Aurora-A needs to be further investigated, previous
studies have implicated some other APC/C targets to HCC,
such as Aurora B (Lin et al., 2010) and L2DTL (Pan et al.,
2006). A recent study carried on Drosophila indicated that irradi-
ation-induced hormetic effect was only revealed in Sirt2 mutant
males but not in females (Moskalev et al., 2011). Thus, the
gender difference in cellular stress resistance and tumorigenesis
associated with SIRT2mutation should be interesting topics and
deserve further investigation in the future.
Of note, the APC/C and most of its main regulators are essen-
tial for the development, as knockouts of any of these proteins
cause embryonic lethality or early postnatal death (Wirth et al.,
2004; Lee et al., 2006), whereas SIRT2/ mice are born at
normal mendelian ratio. We believe this is mainly because
SIRT2 deficiency leads to a reduced, but not complete knockout
of APC/C, activity, which is sufficient to support their develop-
ment although the aged mutant mice displayed spontaneous
tumorigenesis. In this regards, it was shown that mice heterozy-
gous for CDH1 (Garcı´a-Higuera et al., 2008), CDC20 (Li et al.,
2009), MAD1 (Iwanaga et al., 2007), and MAD2 (Michel et al.,
2001) are developmentally normal, but suffered from tumorigen-
esis at later stages. Thus, reduced APC/C activity in SIRT2
mutant mice, although does not impair development of the
mutant mice, eventually results in tumor formation.
In summary, we demonstrated that SIRT2 regulates APC/C
activity through deacetylating its coactivators, CDH1 and
CDC20. Loss of SIRT2 consequently causes increased levels
of many mitosis regulators that may contribute to centrosome
amplification, aneuploidy, mitotic cell death, and most impor-
tantly spontaneous tumor formation (Figure 8F). In addition,
SIRT2 expression is reduced in several human malignancies
including breast, liver, brain, kidney, and prostate cancers.
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Thus, these results identify SIRT2 as a fidelity or tumor sup-
pressor gene and uncover an essential role for SIRT2 inmaintain-
ing the integrity of mitosis through positively regulating APC/C
activity, a dysfunction of which leads to genetic instability and
tumorigenesis.
EXPERIMENTAL PROCEDURES
Mating and Genotyping Mice
Chimeric mice, obtained by injecting the targeted Sirt2+/ ES cells into blasto-
cysts, were mated with NIH Black Swiss or C57B6 females to screen for germ-
line transmission. Male mice bearing germline transmission were mated with
female FVB EII-Cre mice (Lakso et al., 1996) to generate complete deletion
of Sirt2 exons 5–8. The animals were genotyped using either Southern blot
or PCR with the following primers: primer 1, 50 GCCTTAGCTACATAGAAGGC
30; primer 2, 50 GAATGACCTACAATGGGCCA 30; and primer 3, 50 GTGTAGC
CCTGGCTCTTCTA 30. Primers 1, 2, and 3 are located within introns 4, 7,
and 8, respectively. Primers 2 and 3 amplify the wild-type allele (200 bp) and
floxed allele (255 bp). The combination of primer 1 and 3 amplifies the deleted
allele (350 bp). All experiments were approved by the Animal Care and Use
Committee of the National Institute of Diabetes, Digestive and Kidney
Diseases (ACUC, NIDDK).
Clinical Specimens
The tissue array of breast cancer samples was purchased from US Biomax
(Cat. BR1002). All tissues were collected with the donor being informed
completely and with their consent and the samples were subsequently de-
identified prior to analysis. Immunohistochemical staining against SIRT2
(Cat. S8447, Sigma) was carried out with a HistoMouse-SP (AEC) kit (Cat.
95-9544, Zymed). cDNAmicroarray analysis from 264 hepatic cell carcinomas
was as previously described (Yamashita et al., 2008). The validation of
microarray data was carried out by qRT-PCR with the following primers:
SIRT2-RT-F1, CCGGCCTCTATGACAACCTA; SIRT2-RT-R1, GGAGTAGCC
CCTTGTCCTTC; 18S-F1, AGTCCCTGCCCTTTGTACACA; and 18S-R1, CGA
TCCGAGGGCCTCACTA. Use of human tissues was approved by the NIH
Office of Human Subjects Research.
Purification of SIRT2-Associated Proteins
HeLa cells, transiently transfected with Flag-SIRT2 or pCMV vector by Fugene
6 (Roche Applied Science, Indianapolis, IN), were lysed with IP buffer (10 mM
HEPES, Ph 7.9, 180 mM KCl, 1.5 mM MgCl2, 0.1% NP-40, 1 mM EDTA,
0.1 mM PMSF), including protease inhibitors. Total cell extracts were incu-
bated with anti-Flag M2 agarose (Sigma, St. Louis, MO) for 12 hr at 4C. After
washing five times with IP buffer, bound proteins were eluted using 0.25mg/ml
Flag peptide (Sigma), concentrated using a microcon column (Millipore),
resolved by 4%–12% SDS-PAGE, stained with Coomassie blue, and analyzed
via in-gel digestion followed by liquid chromatography-mass spectrometry.
Growth Curve, Chromosome Spread, and Mitotic Exit Analysis
For growth properties, primary MEFs were plated at a density of 5 3 105 cells
per 100-mm dish, and the number of cells counted using the classical 3T3
protocol. Chromosome spread was conducted as previously described
(Deng and Xu, 2004). Briefly, cells in an exponentially growing plate are treated
for 1 hr with Colcemid at a final concentration of 0.01 mg/ml. Cells are then
treated with 0.56% KCl and fixed with ice cold fixative for three times. Gently
suspend cells in the fixative and drop a small quantity of the suspension using
a Pasteur pipette on glass slides. After air dry, the slides are stained with
Giemsa (based on manufacturer’s instructions).
For mitotic exit analysis, primary MEFs were synchronized, using the double
thymidine block method, followed by treatment with nocodazole, and harvest-
ing of mitotic cells. The mitotic cells were washed three times with PBS, incu-
bated with standard DMEM containing 15% FBS, and harvested at indicated
time points. The harvested samples were analyzed usingwestern blot analysis.
Immunohistochemical Staining
For immunohistochemical staining, tissues were fixed in 10% formalin,
blocked in paraffin, sectioned, stained with hematoxylin and eosin, and
analyzed by light microscopy. Detection of primary antibodies was carried
out using the Zymed Histomouse SP Kit (Invitrogen) following the manufac-
turer’s instructions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and one table and can be
found with this article online at doi:10.1016/j.ccr.2011.09.004.
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